Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

• Authors: Ali Ibrahim, American University of Beirut; Nour Moukalled, Emory University; Rami Mahfouz, American University of Beirut; Jean El Cheikh, American University of Beirut; Ali Bazarbachi, American University of Beirut; Iman Abou Dalle, American University of Beirut
• Journal Title: Clinical Hematology International
• Volume: Volume 4, Number 1-2
• Publisher: Springer | 2022-06-01, Pages 30-34
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1007/s44228-022-00001-x
• Subjects: Health Sciences, Oncology; Health Sciences, Medicine and Surgery
• Keywords: CML; Chronic phase; Imatinib; Nilotinib; Cytogenetic response; Maintenance therapy

Abstract

The treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) with nilotinib has resulted in a higher rate of major molecular (MMR) and complete cytogenetic response (CCyR) at 12 months compared to imatinib but at a higher cumulative cost and increased risk of serious adverse events. To maintain long-term efficacy and minimize both toxicity and costs, we aimed at evaluating in a prospective single-center trial the efficacy and safety of a response-directed switch from nilotinib to imatinib after 12 months in patients newly diagnosed with chronic phase CML. Thirteen adult patients were enrolled. Twelve patients started on nilotinib 300 mg twice daily. Eleven patients completed one year of nilotinib and were switched to imatinib 400 mg daily as per protocol. At 3 months, all patients achieved a complete hematologic response, with 7 (58%) patients had early molecular response. At 12 months, all patients achieved CCyR, of whom 5 (42%) and 4 (33%) patients achieved MMR and MR4.5, respectively. Three (27%) patients switched back to nilotinib after 18, 24, and 51 months respectively: 1 patient because of loss of CCyR after 18 months, and 2 patients because of imatinib intolerance. At last follow-up, all patients (n = 12) were alive and in MMR, 6 (50%) of them in continuous MR4.5. These findings suggest that response directed switch from nilotinib to imatinib at 12 months is capable of maintaining long-term response, with manageable side effects. This approach warrants further exploration with larger prospective trials.